Find a consultant
Find a consultant
Our consultant directory offers information on who our consultants are, their specialities and where they are based.
If you have an enquiry relating to your appointment or your treatment, you should contact the relevant department instead of your individual consultant to ensure that our clinical support team can provide you with the right support to your enquiry in a timely manner.
Find a consultant
Our consultant directory offers information on who our consultants are, their specialities and where they are based.
If you have an enquiry relating to your appointment or your treatment, you should contact the relevant department instead of your individual consultant to ensure that our clinical support team can provide you with the right support to your enquiry in a timely manner.
Professor John Gribben
St Bartholomew's Hospital at ConsultantProfessor Gribben graduated from Glasgow University Medical School in 1980. He was awarded MRCP in 1983, FRCPath in 1989 and FRCP in 2000. He completed a Leukaemia Research Fund Fellowship and then a Wellcome Trust Research Fellowship at UCL and an MRC Fogarty Fellowship at Harvard Medical School where he completed studies that led to his MD and DSc.
He completed his oncology fellowship at Dana-Farber Cancer Institute, Harvard Medical School. Thereafter, he joined the Faculty of Harvard medical School in 1992 and was Associate Professor of Medicine at Harvard Medical School until his return to Barts in 2004.
He was admitted as a Fellow of the Academy of Medical Science in 2008.
He has published over 525 peer reviewed articles and numerous books and book chapters.
He is the Centre Lead for the Centre for Haemato-Oncology at Barts Cancer Institute, QMUL.
Treatments and procedures
- Director, Stem Cell Transplantation and Immune Effecor Cells, Barts Health NHS Trust
- Offers treatment of acute and chronic leukaemias, non-Hodgkin lymphoma and Hodgkin disease
Research interests
Professor Gribben’s research interests focus on the impact of cancer on the host immune system and steps that can be taken to improve immunological responses against cancer.
His work on basic immunology identified key costimulatory and immune checkpoint inhibitors. His work on cancer immunology identified molecular mechanisms leading to T cell exhaustion in cancer. He was a leading figure in the identification of the importance of the assessment of measurable residual disease (MRD) as a prognostic marker in leukaemia and lymphoma and after stem cell transplant
Leadership roles
- Professor Gribben is the Centre Lead for the Centre for Haemato-Oncology at Barts Cancer Institute.
- He was Director of the North East London Cancer Research Network from 2005 to 2014
- He was Director, Research and Development, Barts and The London from 2009 to 2013.
- He is Chair of the international workshop for NHL
- He is co-Chair of the international workshop for CAR-T cells
- He has served on the Board of the European Hematology Association from 2014 to present and was President of EHA from 2019-2021
Speciality
Haemato-Oncology
Consultant services
Cancer
Languages Spoken
English
Available for private patient work
Yes, find out more
GMC number
2548364
Record last modified